In vitro study | BMS-911543 in SET-2 and BaF3-V617F cell lines, with potent antiproliferative activity (IC50 60 nM and 70 nM, respectively). This activity is associated with inhibition of the persistently activated pSTAT5 activity. In contrast, non-jak2-dependent cell lines such as A549, MDA-MB-231, MiaPaCa-2 significantly less sensitive to treatment with the inhibitor. Cell lines dependent on other JAK family members, including CTLL2 and IL-3-stimulated BaF3 cells, have weak antiproliferative activity against BMS-911543 (IC50 2.9 and 3.5 μm, respectively). |
In vivo study | BMS-911543 suppressed pSTAT5 levels in a mouse model stimulated with thrombopoietin (TPO). This response was dose-dependent, resulting in a complete return to normal pSTAT5 levels at the highest oral dose of 30 mg/kg, which was maintained for 18 hours. At a moderate oral dose of 10 mg/kg, pSTAT5 levels were reduced by 65%; Instead, at a dose of 5 mg/kg, pSTAT5 levels were reduced by 50% and maintained for 8 hours. The observed decrease in pSTAT5 was associated with BMS-911543 treatment, with AUC0-8h of 23, 41 and 109 μm · h at 5, 10 and 30 mg/kg, respectively. The absolute oral bioavailability of BMS-911543 in liquid form is greater than 50% in mice, rats, dogs and monkeys. In addition, the absorption of BMS-911543 is not significantly affected by the particle lysate (suspension formulation), and its relative oral bioavailability (ratio of suspension to liquid) in rats is about 60%; In dogs, its relative oral bioavailability is almost 100%. |